HAYWARD, Calif.--(BUSINESS WIRE)--
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that
Bryan M. Reasons has been appointed senior vice president and chief
financial officer (CFO). Mr. Reasons, 45, joined Impax Laboratories in
January 2012 as vice president, Finance, and has served as acting CFO
since June 2012.
“Following a nationwide search, Bryan Reasons was selected as the best
candidate to fill the CFO role,” said Larry Hsu, Ph.D., president and
CEO, Impax Laboratories. “He has a breadth of knowledge across
accounting and finance, combined with extensive merger and acquisition
experience within the pharmaceutical industry. In less than two years,
we have significantly transformed Impax’s leadership team across a
number of functions as we focus on executing our growth strategy.”
Prior to joining Impax Laboratories, Mr. Reasons served as vice
president, Finance, and as vice president, Risk Management and General
Auditor, at Cephalon, Inc. (Cephalon), a biopharmaceutical company.
Following the acquisition of Cephalon by Teva Pharmaceutical Industries
Ltd. (Teva), he served briefly as the vice president, Finance, of Teva.
Prior to joining Cephalon in 2005, Mr. Reasons held various finance
management positions at Dupont and began his career at
PricewaterhouseCoopers LLP, where he held positions of increasing
responsibility. He earned a bachelor’s degree in accounting from the
Pennsylvania State University and an M.B.A. from Widener University and
is a certified public accountant.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded products.
Impax markets its generic products through its Global Pharmaceuticals
division and markets its branded products through the Impax
Pharmaceuticals division. Additionally, where strategically appropriate,
Impax has developed marketing partnerships to fully leverage its
technology platform. Impax Laboratories is headquartered in Hayward,
California, and has a full range of capabilities in its Hayward,
Philadelphia and Taiwan facilities. For more information, please visit
the Company's Web site at: www.impaxlabs.com.
Source: Impax Laboratories, Inc.